RAPP - CIK 0002012593
The table below shows Rapport Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 |
|---|---|---|---|
| Operating cash flow | -$13.06M | -$20.24M | -$17.61M |
| Capital expenditure | $86.00K | $291.00K | $1.07M |
| Investing cash flow | $37.94M | $21.03M | -$41.93M |
| Dividends paid | - | - | - |
| Stock buybacks | - | - | - |
| Financing cash flow | $531.00K | $5.00K | $63.66M |
Rapport Therapeutics, Inc. reported operating cash flow of -$87.47M for fiscal year 2025. That is down 34.9% from -$64.83M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.